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Abstract
Background: The role of Epstein-Barr (EBV) virus in central nervous system (CNS) infections is not fully resolved. It
is clearly associated with lymphoproliferative disease of immunosuppressed persons, and may cause encephalitis.
Methods: We reviewed the medical records, imaging and laboratory findings of all patients EBV DNA PCR positive
in cerebrospinal fluid (CSF) during 2000 to 2009 in the Helsinki University Central Hospital.
Results: We identified 32 patients with EBV DNA in CSF. 11 had history of allogeneic hematopoietic stem cell
transplantation, 7 solid organ transplantation and 5 HIV/AIDS. 5 patients had no preceding immunodeficiency.
In 8 of the cases, another pathogen was identified in CSF. These were M. tuberculosis (2), T. gondii (2), Aspergillus (1),
Herpes simplex virus 1 (1), C. neoformans (1) and Human herpesvirus 6 (1). Altogether in 15/32 (47%) of the cases the
clinician had a strong suspicion of cause other than EBV for the patients’ CNS symptoms/findings.
Of note, 7 of 11 (64%) patients with stem cell transplantation had encephalitis (univariate odds ratio 5.6; confidence
Interval 1.1-27.4). Of these 6 had no other pathogen identified.
Conclusions: EBV DNA was often found together with other microbial findings in CSF of immunocompromised
patients. EBV seems to be associated with encephalitis in stem cell transplant recipients.
Background
Epstein-Barr virus infects over 90% of the world popula-
tion and is the causative agent of infectious mononu-
cleosis. Reactivation of latent EBV is clinically significant
in immunocompromised patients and as a rule accom-
panies lymphoproliferative disease [1].
Central nervous system (CNS) complications of Epstein-
Barr virus (EBV) infection occur in 1 to 18% of patients
with infectious mononucleosis and include encephalitis,
meningitis, cerebellitis, polyradiculomyelitis, transverse
myelitis, cranial and peripheral neuropathies, and psychia-
tric abnormalities [2-4]. EBV is associated with CNS lym-
phoma and encephalitis, and EBV viral load in CSF is
higher than in postinfectious complications [4]. However,
this study had a highly selected patient material, e.g. 50%
had central nervous system lymphoma.
On the other hand EBV-DNA was commonly detected
in CSF of HIV patients with other CNS infections or dis-
eases [5]. In 208 patients with various neurological
diseases, among whom the clinician did not request any
herpesvirus PCR, no CSF sample was found positive for
EBV [6]. Among 253 encephalitis patients studied in
France in 2007, only 2,3% had EBV as etiology [7]. How-
ever, not all of the patients were tested for EBV.
We wanted to study the clinical significance of CNS
EBV DNA positivity in an unselected patient material at
a single tertiary care hospital.
Methods
Positive EBV DNA findings in CSF were identified in the
laboratory database of the Helsinki University Central
Hospital. Patients with medical records available were
included in the study.
We reviewed retrospectively the clinical and laboratory
records as well as the radiologist’s statements of brain
imaging done at the time EBV DNA positivity in CSF.
The clinical diagnosis of encephalitis was based on
brain dysfunction (altered mental status with focal neu-
rological signs or symptoms indicative of parenchymal
brain involvement) in addition to inflammatory and
meningeal symptoms.
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The requests for the CSF PCR examinations came
from individual clinicians on clinical grounds only, with-
out knowledge of this study.
Underlying disease, stem-cell transplantation, solid
organ transplantation and presence of other microbiolo-
gical findings in central nervous system were recorded.
The study was approved by the ethical and personal
data security authorities of the hospital.
Radiology
The brain MRI studies performed at the time of EBV posi-
tivity were retrospectively reanalyzed by one neuroradiolo-
gist (M.P.).
EBV PCR
The DNA was isolated by by using the easyMAG Instru-
ment (bioMérieux). The quantitative real-time EBV PCR
assay for cerebrospinal fluid was performed as previously
described for plasma samples [8,9]. Briefly, the primers
amplifying a conserved sequence of viral DNA polymerase
(BALF5) gene and a fluorogenic probe for this area
described by Kimura et al. were used at a primer concen-
tration of 0.9 uM and a probe concentration of 0.25 uM.
The amplification was carried out in an ABI PRISM 7900
HT Sequence Detector (PE Applied Biosystems) and the
standard curve was created with the Sequence Detection
System software by plotting the CT values against known
EBV-DNA concentrations. The assay has a detection limit
of 500 genome equivalents/ml.
Serology
When available, results of EBV serology including VCA-
IgG, IgM and IgG avidity [10] were recorded to assess
whether the patient had primary infection or reactivation.
Statistical analysis
Categorical variables were analysed by cross-tabulation,
and Fisher’s exact test was used to assess significance.
Continuous variables were compared between the groups
using Mann-Whitney-U test. All calculations were done
with PASW18 (SPSS Inc, Chicago, IL, USA).
Results
Altogether 322 EBV PCR studies of CSF samples from
the Meilahti Hospital of Helsinki University Hospital
were performed during 2000-2009.(Table 1). Additional
samples from other hospitals were not included in this
study.
There were 32 patients with one or more EBV DNA
positive cerebrospinal fluid samples.
Most hospital patients with EBV DNA in CSF are
immunosuppressed
Of the 32 patients 26 (81%), had an immunosuppressive
condition: 11 had history of allogeneic hematopoietic
stem cell transplantation, 7 solid organ transplant and 5
HIV/AIDS. In addition 2 patients had hematological
malignancy without stem cell transplantation, and one
had IgG subclass deficiency. One patient had a suspicion
of lymphoma at the time of EBV finding and died of
pneumocystis infection and sepsis. 5/32 (16%) patients
had no preceding immunodeficiency. Two of these had
a clinical picture consistent with mononucleosis and one
patient had multiple sclerosis diagnosed at the time of
EBV DNA positivity in CSF.
EBV is commonly found together with other CNS
infections
In 8 (25%) of the cases another pathogen was verified in
CSF in addition to EBV. These were M. tuberculosis (2),
T. gondii (2), Aspergillus (1), Herpes simplex virus 1 (1),
C. neoformans (1) and Human herpesvirus 6 (1). Alto-
gether in 15/32 (47%) of the cases the clinician had a
strong suspicion of cause other than EBV for the CNS
symptoms/findings based on clinical, laboratory, radiolo-
gical findings, response to therapy, or a microbiological
finding in a site other than CNS together with concor-
dant clinical/radiological findings.
Table 1 Number of CSF EBV PCR tests performed in Meilahti Hospital of Helsinki University Hospital
CSF EBV PCR tests Positive CSF samples in study
2000 7 0
2001 11 1
2002 28 6
2003 23 4
2004 41 2
2005 27 0
2006 49 15
2007 52 5
2008 44 10
2009 40 5
Total 322 48
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In addition one patient developed aspergillus brain
abscess 9 months after the EBV (and HSV) positivity,
following a relapse of acute mixed lineage leukaemia.
The seven clinically suspected pathogens without
microbiological confirmation included tuberculosis/
mycobacterial infection in 2 cases, toxoplasma (1) and
aspergillus (1), nocardia (one patient, with prior lung
nocardiosis and response of CNS lesions to merope-
nem), JC-virus (one moribund patient with MRI findings
typical of PML), VZV (1) and suspected bacterial/fungal
infection (1). (Table 2)
Clinical manifestations
In 13 cases clinical diagnosis of encephalitis or menin-
goencephalitis was made. In 6 patients the clinical diag-
nosis was meningitis without encephalitis.
Interestingly, 7 of 11 stem cell transplant recipients
had encephalitis, compared to 1 of 7 solid organ trans-
plant recipients and 1 of 5 HIV infected patients. The
univariate odds ratio for HSCT versus no HSCT to have
encephalitis was 5.6 (confidence interval 1.1-27.4)
(Figure 1)
In the remaining patients the clinical/radiological diag-
noses included brain abscess (tuberculosis, bacteria,
fungi, toxoplasma) (7), CNS lymphoma/lymphoprolifera-
tive disease (4), mononucleosis with facial paresis (1),
multiple sclerosis (1) and pontine myelinolysis (1)
(Table 2)
Imaging studies
30 patients had at least one brain magnetic resonance
imaging performed at the time of CSF EBV DNA posi-
tivity. For this study our neuroradiologist reviewed the
MRI scans in retrospect with similar criteria.
Among the, 7 stem cell transplant patients with ence-
phalitis, 4 had normal MRI at the time of CSF EBV DNA
positivity. One had only computed tomography per-
formed initially. One had unenhancing patchy changes
both supra- and infratentorially, compatible with ence-
phalitis. Another patient had a hemorrhagic lesion in the
cerebellum and small changes supratentorially, suggest-
ing mold infection. Despite broad spectrum antibiotics
and voriconazole the patient recovered only after
rituximab.
In the 7 patients with solid organ transplantation, only
one had normal MRI. In 5 patients there were single or
multiple contrast enhancing lesions, and in 4 of these
neuroradiologist suggested lymphoproliferative disease or
infection (tuberculosis in 3 cases, of whom one was con-
firmed microbiologically, and also the remaining 2
received empirical antituberculous therapy). One patient
withmultiple edematous lesions with hemorrhages and
enhancement, suggesting fungus, responded clinically to
voriconazole. In addition one patient with unenhancing
lesions considered in retrospect suggestive of fungus, had
disseminated PTLD, with a brain biopsy positive for EBV
encoded RNA (EBER).
None of the five HIV patients had normal MRI: one
had findings compatible with B-cell lymphoma, two had
toxoplasma lesions, one had PML, and one a small focal
change compatible with cryptococcal meningitis.
Three previously healthy patients had varied changes
compatible with the clinical picture: contrast enhancement
of facial nerves in facial paresis following mononucleosis
in one patient, acute disseminated encephalomyelitis
in another and lesions in cerebellar peduncles and radices
in a patient with meningoencephalitis followed by
polyradiculitis.
CSF cells and chemistry
The median amount of white blood cells and protein in
CSF was higher in the patients with an additional patho-
gen. However, the variation was great and the difference
not significant (Figure 2).
Viral load in CSF
A quantitative real time PCR was used in the study, but
since the quantitation was at the time only validated for
plasma samples, the clinician received the result as
either positive or negative. Viral load should here be
regarded as semi-quantitative. Retrospectively, a CSF
viral load was available for 8 of the 32 patients. The
copy number ranged from 186 to 76,800 copies/ml. The
highest copy number occurred in a PTLD patient.
Viral load in plasma
EBV PCR in plasma was examined in 28 patients, in 22
within one week of the CSF sample. The plasma PCR at
any time was positive in 14 patients.. The plasma viral
loads ranged from 530 to 1,040,000 copies/ml. with the
highest copy numbers again found in the PTLD patients.
In patients with EBV as the sole CNS pathogen (found
or suspected), 9 of 14 had positive plasma EBV PCR, com-
pared to 4 of 13 patients with other concomitant CNS
infections (OR 4.05, CI 0.85-19.35).
Serology
EBV antibodies had been studied in 25 of the 32 patients.
Only 2 had positive IgM and low IgG avidity indicating
primary EBV infection. These were previously immuno-
competent patients with mononucleosis. Two more had
borderline IgM. One of these was a solid organ transplant
recipient with persistently negative EBV IgG and pro-
longed viremia, diagnosed later with EBER-positive
PTLD.
The remaining patients were EBV IgG positive and
IgM negative indicating existing EBV immunity and
reactivation rather than primary infection.
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Table 2 Clinical characteristics of patients with EBV DNA in CSF cerebrospinal fluid
Age Sex Underlying
disease
Immunocompromise Central nervous system
diagnosis
MRI reanalyzed Suspected CSF-
pathogen
Confirmed other CSF
pathogen
encephalitis
65 m AML HSCT encephalitis Normal 1
50 m Myeloma HSCT encephalitis Normal 1
60 f Myelofibrosis HSCT encephalitis Fungus? 1
34 m Hybrid leukaemia HSCT encephalitis HSV1 HSV1 1
40 m AML HSCT encephalitis Normal 1
27 m CML HSCT encephalitis Encephalitis 1
41 f AML HSCT encephalitis Normal VZV 1
53 m MDS HSCT mass lesion Aspergillus Aspergillus Aspergillus 0
38 m CML HSCT meningitis (Polyradiculitis?) Nocardia HHV6 0
39 m ALL HSCT PTLD Infection?? 0
58 f CML HSCT pontine myelinolysis Pontine myelinolysis 0
67 m Kidney TX SOT cerebritis/PTLD Tuberculosis/lymphoma? Tuberculosis Tuberculosis 0
67 f Kidney TX SOT encephalitis/brain abscess Lymphoma?(tuberculosis?) Tuberculosis 1
25 m Kidney TX SOT Mass lesion infection? Aspergillus 0
53 m Heart TX SOT PTLD Fungus? 0
63 m Heart TX SOT Mass lesion Infection or LPD Bacteria or fungi 0
66 m Heart TX SOT Meningoencephalitis or PTLD? Lymphoproliferation?
(Tuberculosis?)
Tuberculosis 0
45 f Lung TX SOT Meningitis Normal 0
32 f HIV AIDS Encephalitis PML JC-Virus 1
33 m HIV AIDS B-cell lymphoma Lymphoma 0
47 m HIV AIDS Mass lesion Toxoplasma Toxoplasma 0
35 m HIV AIDS Mass lesions Toxoplasma Toxoplasma Toxoplasma 0
48 m HIV AIDS meningitis Cryptococcal meningitis Cryptococcus Cryptococcus 0
64 m CLL Mass lesions Toxoplasma Toxoplasma Toxoplasma 0
26 m Multiple sclerosis Immunocompetent Multiple Sclerosis Multiple Sclerosis 0
33 m Mononucleosis Immunocompetent Mononucleosis+facial paresis Neuritis 0
52 f T-cell lymphoma Lymphoma Encephalitis?? 0
27 m Tuberculosis Immunocompetent meningitis+abscess Tuberculous meningitis+abscess Tuberculosis Tuberculosis 0
56 f Myeloma Encephalitis Infection, toxoplasma?/Fungus? 1
46 f Ig subclass
deficiency
meningitis 0
18 f Mononucleosis Immunocompetent meningoencephalitis Polyradiculitis? 1
34 m Viral meningitis Immunocompetent encephalitis Encephalitis? ADEM? 1
HSCT = stem cell transplantation, SOT = solid organ transplant
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Outcome
Ten patients died during the follow-up. with a median sur-
vival time of 41 days (range 5 to 1073). All four patients
with malignant CNS lymphoproliferative disease died.
Two patients died of aspergillosis.
However, only one of the 7 stem cell transplant patients
with clinical encephalitis died during the follow-up. The
deceased patient died 348 days after observed CSF EBV
positivity, due to disseminated (including CNS) aspergillo-
sis. The patient also had HSV1 DNA positivity concomi-
tant with EBV DNA. Therefore the prognosis of EBV
encephalitis in stem cell transplant recipients seems to be
relatively favorable.
Discussion
In this study we observed EBV DNA mainly in the CSF of
severely immunocompromised patients with central
nervous system disease. This finding is consistent with
earlier studies [4] with majority of patients having an
immunosuppressive condition.
In addition to EBV in 8 cases another pathogen was
found in CSF, and in further 7 cases the clinician finally
suspected other etiology based on radiological, biochem-
ical or clinical features or response to therapy. In 17 of our
32 patients EBV was the only pathogen found or sus-
pected. Of these 17 patients, 7 had encephalitis, 3 menin-
gitis and 4 CNS lymphoproliferative disease.
In another study coinfection with another pathogen was
found in 25% of cases with EBV DNA in the CNS [11]
with evidence of EBV replication in the CNS.
In miscellanous neurological patients CNS “coloniza-
tion” with EBV seems to be rare [6,7]. However, in infec-
tious mononucleosis the CSF is often positive for EBV.
Our (and others’)cohort is probably heavily biased by the
clinicians propensity to look for EBV in CNS mainly in
profoundly immunocompromised patients.
Most of our patients had serology consistent with past
EBV immunity and reactivation. This could imply that
other infections in the CNS may trigger EBV reactivation.
Surprisingly, EBV DNA was found in CSF also in the
absence of plasma EBV DNA. Unfortunately this was not
consistently examined in this patient material. In many
cases there was delay between the CSF and plasma sam-
ples, which could explain the negative plasma PCR in
cases of transient viremia. An intriguing alternative expla-
nation is the preferential EBV replication in the CSF possi-
bly stimulated by other CNS infections. Technically, there
should be no difference in the sensitivity of the assay. Clin-
icians should be encouraged to order simultaneous plasma
EBV assay whenever studying EBV DNA from the CSF.
Unfortunately, at present no simple way seems to exist
to determine whether EBV is the cause of an individual
patient’s CNS disease. Exclusion of other pathogens,
absence of brain abscess-like lesions (with the caveat of
lymphoma) and high concomitant plasma level of EBV
DNA, and perhaps history of allogeneic stem cell trans-
plantation in the context of encephalitis can support a pri-
mary role for EBV.
Inpatients with EBV DNA in the CSF a consideration
of reduction of immunosuppression, if feasible, is war-
ranted. Rituximab is well established in treatment of EBV
associated lymphoproliferative disease [12]. However its
role in EBV-associated encephalitis is unclear. The same
is true for antiviral agents and i.v. immunoglobulin.
Multiplex PCR tests for simultaneous detection of several
herpesviruses are used increasingly. This will shed more
light on the real frequency of the EBV presence in the CNS
of patients hospitalised due to neurological symptoms,
when also previously healthy individuals will be tested.
Indications to test CSF for EBV DNA include suspi-
cion of CNS PTLD or lymphoma in solid organ- and
 
Figure 1 Clinical manifestations of patients with EBV DNA in
CSF. Y-axis: number of patients. HIV = HIV infection, HSCT = stem
cell transplantation, SOT = solid organ transplantation. “Brain
abscess” also includes fungal lesions.
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Figure 2 Number of leukocytes in CSF (× 106 cells/liter)
Leukocyte number in cerebrospinal fluids with EBV only or
with other pathogens (difference not significant). Box plots
show the median, interquartile range, error bars and outliers.
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stem cell transplant patients and HIV patients. Encepha-
litis in stem cell transplant patients propably warrants
EBV testing of CSF, among other tests. In other patient
groups the indications are less clear but in general, pro-
found deficiency of T-cell mediated immunity predis-
poses to complications of EBV infection.
However, even in these patients, CSF EBV PCR should
be interpreted with caution, and meticulously exclude
other, treatable microbial pathogens.
More studies are needed that include tissue level
demonstration of EBV to demonstrate the pathogenic
role of EBV in CNS diseases other than PTLD.
Conclusions
In immunocompromised patients with EBV DNA in CSF
other microbial pathogens often coexist. Especially in
HSCT patients EBV appears to be a significant CNS
pathogen.
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